Chitra Lal, MD
Sleep Medicine · Salt Lake City, UTNPI 1437197175
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,930 of the $93,758 with a category attached, or 73.5%. Jazz Pharmaceuticals Inc. accounts for 88.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $28,838 and has fallen 98.6% since, to $413 in 2025.
Across 76 payments — averaging $1233.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$83K
- Idorsia Pharmaceuticals US Inc$4K
- Axsome Therapeutics, Inc.$4K
- GSK$2K
- United Therapeutics Corporation$306
- Avadel CNS Pharmaceuticals, LLC$200
- plus $524 from 6 others
What the payments were for
- Consulting fees$68,93074%
- Speaking & faculty fees$14,90016%
- Travel & lodging$6,5207%
- Food & beverage$3,3134%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 54 | $83,255 |
| Idorsia Pharmaceuticals US Inc | 2 | $3,883 |
| Axsome Therapeutics, Inc. | 8 | $3,590 |
| GSK | 1 | $2,000 |
| United Therapeutics Corporation | 3 | $306 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $200 |
| Itamar Medical Inc | 1 | $159 |
| Harmony Biosciences LLC | 1 | $95 |
| Mylan Specialty L.p. | 2 | $91 |
| Genentech USA, Inc. | 1 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $55 |
| Insmed, Inc. | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,758 in reported general payments places this provider in the 85th percentile of 20 sleep medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $246,879 |
| Modafinil | 12 | $1,098 |
| Zolpidem Tartrate ErZolpidem Tartrate | 17 | $529 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Salt Lake City
- Robert MazzolaSalt Lake City$12K
- Nicholas AndersonSalt Lake City$7K
- Sanjay KajiSalt Lake City$5K
- Shannon JenkinsSalt Lake City$2K
- Ann KingSalt Lake City$1K
- Kevin WalkerSalt Lake City$1K
- Robert FarneySalt Lake City$738
- Kevin ShillingSalt Lake City$228
- Paul TemanSalt Lake City$73
- Kallin RaymondSalt Lake City$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.